Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment (Q39571043)

13 September 2017

Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment (English)

1 reference

Burkholderia pseudomallei

13 September 2017

0 references

4

N J White

1 reference

13 September 2017

A L Walsh

1

1 reference

13 September 2017

M D Smith

series ordinal

2

1 reference

13 September 2017

V Wuthiekanun

series ordinal

3

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 October 1995

1 reference

Antimicrobial Agents and Chemotherapy

13 September 2017

3

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

13 September 2017

39

1 reference

13 September 2017

10

1 reference

13 September 2017

2356-2358

1 reference

Relapse in melioidosis: incidence and risk factors

13 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

Halving of mortality of severe melioidosis by ceftazidime

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

The postantibiotic effect induced by antimicrobial combinations.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162945

Comparison of methodologies used in assessing the postantibiotic effect

17 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/8619598

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Synergic post-antibiotic effect of amikacin in combination with β-lactam antibiotics on Gram-negative bacteria

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/8619598

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.39.10.2356

1 reference

release_pfmvbfa6ynfk7nmdttil7cc2li

13 September 2017

0 references

1 reference

13 September 2017

1 reference